Cargando…
Melanoma cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme
The receptor for the urokinase-type plasminogen activator (uPAR) accounts for many features of cancer progression, and is therefore considered a target for anti-tumoral therapy. Only full length uPAR mediates tumor progression. Matrix-metallo-proteinase-12 (MMP12)-dependent uPAR cleavage results int...
Autores principales: | Laurenzana, Anna, Biagioni, Alessio, D'Alessio, Silvia, Bianchini, Francesca, Chillà, Anastasia, Margheri, Francesca, Luciani, Cristina, Mazzanti, Benedetta, Pimpinelli, Nicola, Torre, Eugenio, Danese, Silvio, Calorini, Lido, Rosso, Mario Del, Fibbi, Gabriella |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4116515/ https://www.ncbi.nlm.nih.gov/pubmed/25003596 |
Ejemplares similares
-
EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells
por: Laurenzana, Anna, et al.
Publicado: (2019) -
uPAR-expressing melanoma exosomes promote angiogenesis by VE-Cadherin, EGFR and uPAR overexpression and rise of ERK1,2 signaling in endothelial cells
por: Biagioni, Alessio, et al.
Publicado: (2020) -
CRISPR/Cas9 uPAR Gene Knockout Results in Tumor Growth Inhibition, EGFR Downregulation and Induction of Stemness Markers in Melanoma and Colon Carcinoma Cell Lines
por: Biagioni, Alessio, et al.
Publicado: (2021) -
uPAR Controls Vasculogenic Mimicry Ability Expressed by Drug-Resistant Melanoma Cells
por: Andreucci, Elena, et al.
Publicado: (2022) -
The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style
por: Margheri, Francesca, et al.
Publicado: (2014)